Article(id=1330184372222799926, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330184264366272602, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2023.06.018, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1663603200000, receivedDateStr=2022-09-20, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795070267968, onlineDateStr=2026-11-19, pubDate=1686326400000, pubDateStr=2023-06-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795070267968, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795070267968, creator=13701087609, updateTime=1795070267968, updator=13701087609, issue=Issue{id=1330184264366272602, tenantId=1146029695717560320, journalId=1319690259887390882, year='2023', volume='54', issue='6', pageStart='813', pageEnd='981', issueExtLink='null', onlineDate='null', pubDate='1686326400000', pubDateStr='2023-06-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795070242253, creator='13701087609', updateTime=1795080494688, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330227266719691144, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330184264366272602, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330227266719691145, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330184264366272602, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=957, endPage=964, ext={EN=ArticleExt(id=1330184372415737911, articleId=1330184372222799926, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Status and Analysis of Domestic and Foreign Laws and Regulations on Accelerated CMC Development and Registration of Innovative Therapeutic Biological Products, columnId=1322624444787438528, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Pharmaceutical Management & Information, runingTitle=null, highlight=null, articleAbstract=null, authors=Xianglin LYU1, Yaying WANG2, Xiaohua ZHANG2, Ming CHEN2, Linqi ZHANG1, authorsList=Xianglin LYU, Yaying WANG, Xiaohua ZHANG, Ming CHEN, Linqi ZHANG, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330184373393010745, articleId=1330184372222799926, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=加速创新型治疗用生物制品CMC开发与注册的国内外法规现状与分析, columnId=1322624444934239170, journalTitle=中国医药工业杂志, columnName=药学管理与信息, runingTitle=null, highlight=null, articleAbstract=

我国正式加入人用药品技术要求国际协调理事会(ICH),药品审评审批制度改革以及新法规指导原则的实施,为鼓励创新药在全球的同步开发和上市创造了良好的环境。近年来,为支持有迫切临床需求的创新药尽快上市,国内外药品监管机构陆续出台了多种加速途径。化学、制造和控制(CMC)与临床研究的同步开发直接关系到临床研究样品和上市产品的供应,创新药整体开发进程的加速给常规的CMC开发速度带来新的挑战。该文通过对目前国内外相关法规和文献的梳理和分析,探讨了如何基于风险-获益平衡的思想科学监管,通过新技术、生产和控制策略的引入加速CMC开发,以支持创新药更快进入临床研究以及更快上市惠及患者。

, authors=吕香霖1, 王雅英2, 张小华2, 陈明2, 张林琦1, authorsList=吕香霖, 王雅英, 张小华, 陈明, 张林琦, authorCompany=null, correspAuthors=null, authorNote=

吕香霖(1989—),女,博士,从事药品监管科学的研究。E-mail:

, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=9w/rVGZH8tn+xiOq1gYjSg==, magXml=F6KZO4owRS4xRU7QsjLFJw==, pdfUrl=null, pdf=fDQ28nYMsfOsKxE28U3xrw==, pdfFileSize=1526744, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=weS7IY8ekcCUXA7j//zENg==, mapNumber=null, fund=null)}, authors=[Author(id=1330184374609358913, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=xianglinlv@aliyun.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330184374701633603, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184374609358913, language=EN, stringName=Xianglin LYU, firstName=Xianglin, middleName=null, lastName=LYU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.School of Medicine, Tsinghua University, Beijing 100084, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330184374798102596, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184374609358913, language=CN, stringName=吕香霖, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.清华医学院,北京 100084, bio={"content":"

吕香霖(1989—),女,博士,从事药品监管科学的研究。E-mail:

"}, bioImg=null, bioContent=

吕香霖(1989—),女,博士,从事药品监管科学的研究。E-mail:

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330184374454169658, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=1., ext=[AuthorCompanyExt(id=1330184374462558267, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374454169658, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Medicine, Tsinghua University, Beijing 100084), AuthorCompanyExt(id=1330184374470946876, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374454169658, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.清华医学院,北京 100084)])]), Author(id=1330184374869405767, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330184374944903241, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184374869405767, language=EN, stringName=Yaying WANG, firstName=Yaying, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.GlaxoSmithKline Company, Beijing 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330184375003623498, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184374869405767, language=CN, stringName=王雅英, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.葛兰素史克公司,北京 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330184374533861437, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=2., ext=[AuthorCompanyExt(id=1330184374542250046, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.GlaxoSmithKline Company, Beijing 100025), AuthorCompanyExt(id=1330184374550638655, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.葛兰素史克公司,北京 100025)])]), Author(id=1330184375074926668, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330184375154618446, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375074926668, language=EN, stringName=Xiaohua ZHANG, firstName=Xiaohua, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.GlaxoSmithKline Company, Beijing 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330184375217533007, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375074926668, language=CN, stringName=张小华, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.葛兰素史克公司,北京 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330184374533861437, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=2., ext=[AuthorCompanyExt(id=1330184374542250046, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.GlaxoSmithKline Company, Beijing 100025), AuthorCompanyExt(id=1330184374550638655, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.葛兰素史克公司,北京 100025)])]), Author(id=1330184375293030481, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330184375385305171, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375293030481, language=EN, stringName=Ming CHEN, firstName=Ming, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.GlaxoSmithKline Company, Beijing 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330184375464996948, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375293030481, language=CN, stringName=陈明, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.葛兰素史克公司,北京 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330184374533861437, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=2., ext=[AuthorCompanyExt(id=1330184374542250046, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.GlaxoSmithKline Company, Beijing 100025), AuthorCompanyExt(id=1330184374550638655, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.葛兰素史克公司,北京 100025)])]), Author(id=1330184375536300118, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330184375603408984, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375536300118, language=EN, stringName=Linqi ZHANG, firstName=Linqi, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.School of Medicine, Tsinghua University, Beijing 100084, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330184375674712153, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375536300118, language=CN, stringName=张林琦, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.清华医学院,北京 100084, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330184374454169658, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=1., ext=[AuthorCompanyExt(id=1330184374462558267, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374454169658, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Medicine, Tsinghua University, Beijing 100084), AuthorCompanyExt(id=1330184374470946876, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374454169658, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.清华医学院,北京 100084)])])], keywords=[Keyword(id=1330184375766986842, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, language=CN, orderNo=1, keyword=CMC), Keyword(id=1330184375846678620, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, language=CN, orderNo=2, keyword=创新型治疗用生物制品), Keyword(id=1330184375917981789, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, language=CN, orderNo=3, keyword=药品加快上市程序)], refs=[Reference(id=1330184376014450782, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=STEWART D J, STEWART A A, WHEATLEY‐PRICE P, et al. The importance of greater speed in drug development for advanced malignancies [J]. Cancer Med, 2018, 7(5):1824-1836., articleTitle=null, refAbstract=null), Reference(id=1330184376098336863, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. Expedited Programs for Serious Conditions – Drugs and Biologics [EB/OL]. [2014-03]. https://www.fda.gov/media/119293/download., articleTitle=null, refAbstract=null), Reference(id=1330184376161251424, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=DYE E S, GROSKOPH J, KELLEY B, et al. CMC considerations when a drug development project is assigned breakthrough therapy status [J]. Pharm Eng, 2015, 35(1):1-11., articleTitle=null, refAbstract=null), Reference(id=1330184376228360289, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=国务院.关于改革药品医疗器械审评审批制度的意见[EB/OL].[2015-08-18].http://www.gov.cn/zhengce/content/2015-08/18/content_10101.htm., articleTitle=null, refAbstract=null), Reference(id=1330184376278691938, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=国务院办公厅.关于深化审评审批制度改革鼓励药品医疗器械创新的意见[EB/OL].[2017-10-08].http://www.gov.cn/xinwen/2017-10/08/content_5230105.htm., articleTitle=null, refAbstract=null), Reference(id=1330184376341606499, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局.中华人民共和国药品管理法[EB/OL].[2019-08-27].http://www.gov.cn/xinwen/2019-08/26/content_5424780.htm., articleTitle=null, refAbstract=null), Reference(id=1330184376396132452, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=国家市场监督管理总局.药品注册管理办法[EB/OL].[2020-01-22].http://www.gov.cn/gongbao/content/2020/content_5512563.htm., articleTitle=null, refAbstract=null), Reference(id=1330184376459047013, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. Content and Format of Investigational New Drug Applications(INDs) for Phase 1 [EB/OL]. [1995-11]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-investigational-new-drug-applications-inds-phase-1-studies-drugs-including-well., articleTitle=null, refAbstract=null), Reference(id=1330184376526155878, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=EMA. Strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products [EB/OL]. [2007-03-05]. https://www.ema.europa.eu/en/strategies-identify-mitigate-risks-first-human-early-clinical-trials-investigational-medicinal., articleTitle=null, refAbstract=null), Reference(id=1330184376610041959, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=EMA. Requirements for quality documentation concerning biological investigational medicinal products in clinical trials[EB/OL]. [2012-05-14]. https://www.ema.europa.eu/en/requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical., articleTitle=null, refAbstract=null), Reference(id=1330184376681345128, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局.关于发布新药Ⅰ期临床试验申请技术指南的通告[EB/OL].[2018-01-25].https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/qtggtg/20180125135801903.html., articleTitle=null, refAbstract=null), Reference(id=1330184376765231209, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局.关于发布生物制品注册分类及申报资料要求的通告[EB/OL].[2020-07-01].https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20200630175301552.html., articleTitle=null, refAbstract=null), Reference(id=1330184376849117290, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心.关于《临床试验期间生物制品药学研究和变更技术指导原则》(上网征求意见稿)征求意见的通知.[EB/OL].[2020-09-10].https://www.cde.org.cn/main/news/viewInfoCommon/3e7f133e8a854894fafa49752d7d8a9e., articleTitle=null, refAbstract=null), Reference(id=1330184376933003371, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. CGMP for Phase 1 Investigational Drugs [EB/OL]. [2008-07]. https://www.fda.gov/media/70975/download, articleTitle=null, refAbstract=null), Reference(id=1330184377054638188, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=EUROPEAN COMMISSION. Good Manufacturing Practice(GMP) guidelines-Annex 13 [EB/OL]. [2017-08-12]. https://ec.europa.eu/health/medicinal-products/eudralex/eudralex-volume-4_en., articleTitle=null, refAbstract=null), Reference(id=1330184377167884397, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局.关于发布《药品生产质量管理规范(2010年修订)》临床试验用药品附录的公告[EB/OL].[2022-05-27].https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20220527182006196.html, articleTitle=null, refAbstract=null), Reference(id=1330184378786885743, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. Chemistry, Manufacturing, and Control(CMC) Information for Human Gene Therapy Investigational New Drug Applications(INDs) [EB/OL]. [2020-01]. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM610795.pdf., articleTitle=null, refAbstract=null), Reference(id=1330184378904326256, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Friend of Cancer Research. Designing the Future of Cellular Therapies [EB/OL]. [2019-03-31]. https://friendsofcancerresearch.org/wp-content/uploads/Friends_Cellular_Therapies_White_Paper_1.pdf, articleTitle=null, refAbstract=null), Reference(id=1330184378988212337, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=STEWART M D, KEANE A, BUTTERFIELD L H, et al. Accelerating the development of innovative cellular therapy products for the treatment of cancer [J]. Cytotherapy, 2020,22(5): 239-246., articleTitle=null, refAbstract=null), Reference(id=1330184379067904114, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. Regenerative Medicine Advanced Therapy Designation [EB/OL]. [2017]. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation., articleTitle=null, refAbstract=null), Reference(id=1330184379143401587, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=MARCHETTI S, SCHELLENS J H M. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials [J]. Br J Cancer, 2007, 97(5): 577-581., articleTitle=null, refAbstract=null), Reference(id=1330184379210510452, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. Exploratory IND Studies [EB/OL]. [2006-01]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exploratory-ind-studies, articleTitle=null, refAbstract=null), Reference(id=1330184379290202231, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=TEJWANI V, CHAUDHARI M, RAI T, et al. High-throughput and automation advances for accelerating single-cell cloning, monoclonality and early phase clone screening steps in mammalian cell line development for biologics production [J]. Biotechnol Prog, 2021, 37(6): e3208., articleTitle=null, refAbstract=null), Reference(id=1330184379357311096, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=KELLEY B. Developing therapeutic monoclonal antibodies at pandemic pace [J]. Nature biotechnol, 2020, 38(5): 540-545., articleTitle=null, refAbstract=null), Reference(id=1330184379424419961, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG Z, CHEN J, WANG J H, et al. Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak [J]. Biotechnol Prog, 2021, 37(5):e3186., articleTitle=null, refAbstract=null), Reference(id=1330184379483140218, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=MCGOVERN Ā T, SALISBURY C M, NYBERG G B. The pandemic and resilience for the future: AccBio 2021 [J]. Biotechnol Prog, 2022, 38(1): e3207., articleTitle=null, refAbstract=null), Reference(id=1330184379541860475, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=崔靖,宋丽娜.创新单抗药物申报临床试验病毒安全性相关监管指南调研与技术考量[J].药学学报,2021,56(4):2308-2314., articleTitle=null, refAbstract=null), Reference(id=1330184379596386428, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=李敏,郭秀侠,刘伯宁.关于生物制品工艺验证的审评实践与思考[J].中国生物制品学杂志,2017,30(6):664-668., articleTitle=null, refAbstract=null), Reference(id=1330184379667689597, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=EVERS A, CLÉNET D, PFEIFFER-MAREK S. Long-term stability prediction for developability assessment of biopharmaceutics using advanced kinetic modeling [J]. Pharmaceutics, 2022, 14(2): 375., articleTitle=null, refAbstract=null), Reference(id=1330184379743187071, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=CAMPA C, PRONCE T, PALUDI M, et al. Use of stability modeling to support accelerated vaccine development and supply [J]. Vaccines(Basel), 2021, 9(10): 1114., articleTitle=null, refAbstract=null), Reference(id=1330184379818684544, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. Innovative Science and Technology Approaches for New Drugs(ISTAND) Pilot Program [EB/OL]. [2023-03-03]. https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/innovative-science-and-technology-approaches-new-drugs-istand-pilot-program., articleTitle=null, refAbstract=null), Reference(id=1330184379881599105, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=DYE E, STURGESS A, MAHESHWARI G, et al. Examining manufacturing readiness for breakthrough drug development [J]. AAPS PharmSciTech, 2016, 17(3):529-538., articleTitle=null, refAbstract=null), Reference(id=1330184379936125058, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=EFPIA-EBE. White Paper on Expedited CMC Development:Accelerated Access for Medicines of Unmet Medical Need –CMC Challenges and Opportunities [EB/OL]. [2017-12]. https://www.efpia.eu/media/288657/efpia-ebe-white-paper-expedited-cmc-development-accelerated-access-for-medicines-of-unmet-medical-need-december-2017.pdf, articleTitle=null, refAbstract=null), Reference(id=1330184380011622531, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=EMA. Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies [EB/OL]. [2018-11-26]. https://www.ema.europa.eu/en/events/stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-breakthrough, articleTitle=null, refAbstract=null), Reference(id=1330184380078731396, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=ICH Q12. Technical and regulatory considerations for pharmaceutical product lifecycle management [EB/OL]. [2019-12-20]. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf., articleTitle=null, refAbstract=null), Reference(id=1330184380154228869, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. Chemistry, Manufacturing, and Controls Development and Readiness Pilot(CDRP) Program [EB/OL]. [2023-04-01]. https://www.fda.gov/drugs/pharmaceutical-quality-resources/chemistry-manufacturing-and-controls-development-and-readiness-pilot-cdrp-program., articleTitle=null, refAbstract=null), Reference(id=1330184380233920648, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. PQ/CMC and IDMP [EB/OL]. [2023-04-25]. https://www.fda.gov/industry/pharmaceutical-quality-chemistry-manufacturing-controls-pqcmc/pqcmc-and-idmp., articleTitle=null, refAbstract=null), Reference(id=1330184380322001033, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=识林.FDA 药品中心主任谈在云端建立全球质量档案[EB/OL].[2020-01-18].https://mp.weixin.qq.com/s?__biz=MzA5MDAyNjQxMw==&mid=2650393602&idx=1&sn=58e085f9729a2521e68c5dcb36c353e1&chksm=881c94c0bf6b1dd61d671b149eedfb852087deca24ddb395781dd2a76f8aea0d11a30781984d&scene=21#wechat_redirect [EB/OL]., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1330184374454169658, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=1., ext=[AuthorCompanyExt(id=1330184374462558267, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374454169658, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Medicine, Tsinghua University, Beijing 100084), AuthorCompanyExt(id=1330184374470946876, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374454169658, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.清华医学院,北京 100084)]), AuthorCompany(id=1330184374533861437, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=2., ext=[AuthorCompanyExt(id=1330184374542250046, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.GlaxoSmithKline Company, Beijing 100025), AuthorCompanyExt(id=1330184374550638655, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.葛兰素史克公司,北京 100025)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2023.06.018, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2023.06.018, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2023.06.018, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2023.06.018, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1686326400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
加速创新型治疗用生物制品CMC开发与注册的国内外法规现状与分析
吕香霖 1 , 王雅英 2 , 张小华 2 , 陈明 2 , 张林琦 1
中国医药工业杂志 | 药学管理与信息 2023,54(6): 957-964
收起
收藏切换
中国医药工业杂志 |药学管理与信息 2023 , 54 (6) : 957 -964
加速创新型治疗用生物制品CMC开发与注册的国内外法规现状与分析
全屏
[Author(id=1330184374609358913, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=xianglinlv@aliyun.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330184374701633603, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184374609358913, language=EN, stringName=Xianglin LYU, firstName=Xianglin, middleName=null, lastName=LYU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.School of Medicine, Tsinghua University, Beijing 100084, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330184374798102596, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184374609358913, language=CN, stringName=吕香霖, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.清华医学院,北京 100084, bio={"content":"

吕香霖(1989—),女,博士,从事药品监管科学的研究。E-mail:

"}, bioImg=null, bioContent=

吕香霖(1989—),女,博士,从事药品监管科学的研究。E-mail:

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330184374454169658, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=1., ext=[AuthorCompanyExt(id=1330184374462558267, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374454169658, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Medicine, Tsinghua University, Beijing 100084), AuthorCompanyExt(id=1330184374470946876, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374454169658, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.清华医学院,北京 100084)])]), Author(id=1330184374869405767, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330184374944903241, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184374869405767, language=EN, stringName=Yaying WANG, firstName=Yaying, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.GlaxoSmithKline Company, Beijing 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330184375003623498, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184374869405767, language=CN, stringName=王雅英, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.葛兰素史克公司,北京 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330184374533861437, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=2., ext=[AuthorCompanyExt(id=1330184374542250046, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.GlaxoSmithKline Company, Beijing 100025), AuthorCompanyExt(id=1330184374550638655, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.葛兰素史克公司,北京 100025)])]), Author(id=1330184375074926668, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330184375154618446, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375074926668, language=EN, stringName=Xiaohua ZHANG, firstName=Xiaohua, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.GlaxoSmithKline Company, Beijing 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330184375217533007, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375074926668, language=CN, stringName=张小华, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.葛兰素史克公司,北京 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330184374533861437, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=2., ext=[AuthorCompanyExt(id=1330184374542250046, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.GlaxoSmithKline Company, Beijing 100025), AuthorCompanyExt(id=1330184374550638655, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.葛兰素史克公司,北京 100025)])]), Author(id=1330184375293030481, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330184375385305171, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375293030481, language=EN, stringName=Ming CHEN, firstName=Ming, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.GlaxoSmithKline Company, Beijing 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330184375464996948, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375293030481, language=CN, stringName=陈明, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.葛兰素史克公司,北京 100025, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330184374533861437, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=2., ext=[AuthorCompanyExt(id=1330184374542250046, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.GlaxoSmithKline Company, Beijing 100025), AuthorCompanyExt(id=1330184374550638655, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374533861437, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.葛兰素史克公司,北京 100025)])]), Author(id=1330184375536300118, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330184375603408984, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375536300118, language=EN, stringName=Linqi ZHANG, firstName=Linqi, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.School of Medicine, Tsinghua University, Beijing 100084, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330184375674712153, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, authorId=1330184375536300118, language=CN, stringName=张林琦, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.清华医学院,北京 100084, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330184374454169658, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, xref=1., ext=[AuthorCompanyExt(id=1330184374462558267, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374454169658, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Medicine, Tsinghua University, Beijing 100084), AuthorCompanyExt(id=1330184374470946876, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330184372222799926, companyId=1330184374454169658, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.清华医学院,北京 100084)])])]
吕香霖1 , 王雅英2, 张小华2, 陈明2, 张林琦1
作者信息
  • 1.清华医学院,北京 100084
  • 2.葛兰素史克公司,北京 100025
作者简介:

吕香霖(1989—),女,博士,从事药品监管科学的研究。E-mail:

Status and Analysis of Domestic and Foreign Laws and Regulations on Accelerated CMC Development and Registration of Innovative Therapeutic Biological Products
Xianglin LYU1 , Yaying WANG2, Xiaohua ZHANG2, Ming CHEN2, Linqi ZHANG1
Affiliations
  • 1.School of Medicine, Tsinghua University, Beijing 100084
  • 2.GlaxoSmithKline Company, Beijing 100025
出版时间: 2023-06-10 doi: 10.16522/j.cnki.cjph.2023.06.018
文章导航
收藏切换

我国正式加入人用药品技术要求国际协调理事会(ICH),药品审评审批制度改革以及新法规指导原则的实施,为鼓励创新药在全球的同步开发和上市创造了良好的环境。近年来,为支持有迫切临床需求的创新药尽快上市,国内外药品监管机构陆续出台了多种加速途径。化学、制造和控制(CMC)与临床研究的同步开发直接关系到临床研究样品和上市产品的供应,创新药整体开发进程的加速给常规的CMC开发速度带来新的挑战。该文通过对目前国内外相关法规和文献的梳理和分析,探讨了如何基于风险-获益平衡的思想科学监管,通过新技术、生产和控制策略的引入加速CMC开发,以支持创新药更快进入临床研究以及更快上市惠及患者。

CMC  /  创新型治疗用生物制品  /  药品加快上市程序
吕香霖, 王雅英, 张小华, 陈明, 张林琦. 加速创新型治疗用生物制品CMC开发与注册的国内外法规现状与分析. 中国医药工业杂志, 2023 , 54 (6) : 957 -964 . DOI: 10.16522/j.cnki.cjph.2023.06.018
Xianglin LYU, Yaying WANG, Xiaohua ZHANG, Ming CHEN, Linqi ZHANG. Status and Analysis of Domestic and Foreign Laws and Regulations on Accelerated CMC Development and Registration of Innovative Therapeutic Biological Products[J]. Chinese Journal of Pharmaceuticals, 2023 , 54 (6) : 957 -964 . DOI: 10.16522/j.cnki.cjph.2023.06.018

参考文献 引证文献
排序方式:
[1]
STEWART D J, STEWART A A, WHEATLEY‐PRICE P, et al. The importance of greater speed in drug development for advanced malignancies [J]. Cancer Med, 2018, 7(5):1824-1836.
[2]
FDA. Expedited Programs for Serious Conditions – Drugs and Biologics [EB/OL]. [2014-03]. https://www.fda.gov/media/119293/download.
[3]
DYE E S, GROSKOPH J, KELLEY B, et al. CMC considerations when a drug development project is assigned breakthrough therapy status [J]. Pharm Eng, 2015, 35(1):1-11.
[4]
国务院.关于改革药品医疗器械审评审批制度的意见[EB/OL].[2015-08-18].http://www.gov.cn/zhengce/content/2015-08/18/content_10101.htm.
[5]
国务院办公厅.关于深化审评审批制度改革鼓励药品医疗器械创新的意见[EB/OL].[2017-10-08].http://www.gov.cn/xinwen/2017-10/08/content_5230105.htm.
[6]
国家药品监督管理局.中华人民共和国药品管理法[EB/OL].[2019-08-27].http://www.gov.cn/xinwen/2019-08/26/content_5424780.htm.
[7]
国家市场监督管理总局.药品注册管理办法[EB/OL].[2020-01-22].http://www.gov.cn/gongbao/content/2020/content_5512563.htm.
[9]
EMA. Strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products [EB/OL]. [2007-03-05]. https://www.ema.europa.eu/en/strategies-identify-mitigate-risks-first-human-early-clinical-trials-investigational-medicinal.
[10]
EMA. Requirements for quality documentation concerning biological investigational medicinal products in clinical trials[EB/OL]. [2012-05-14]. https://www.ema.europa.eu/en/requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical.
[11]
国家药品监督管理局.关于发布新药Ⅰ期临床试验申请技术指南的通告[EB/OL].[2018-01-25].https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/qtggtg/20180125135801903.html.
[12]
国家药品监督管理局.关于发布生物制品注册分类及申报资料要求的通告[EB/OL].[2020-07-01].https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20200630175301552.html.
[13]
国家药品监督管理局药品审评中心.关于《临床试验期间生物制品药学研究和变更技术指导原则》(上网征求意见稿)征求意见的通知.[EB/OL].[2020-09-10].https://www.cde.org.cn/main/news/viewInfoCommon/3e7f133e8a854894fafa49752d7d8a9e.
[14]
FDA. CGMP for Phase 1 Investigational Drugs [EB/OL]. [2008-07]. https://www.fda.gov/media/70975/download
[15]
EUROPEAN COMMISSION. Good Manufacturing Practice(GMP) guidelines-Annex 13 [EB/OL]. [2017-08-12]. https://ec.europa.eu/health/medicinal-products/eudralex/eudralex-volume-4_en.
[16]
国家药品监督管理局.关于发布《药品生产质量管理规范(2010年修订)》临床试验用药品附录的公告[EB/OL].[2022-05-27].https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20220527182006196.html
[17]
FDA. Chemistry, Manufacturing, and Control(CMC) Information for Human Gene Therapy Investigational New Drug Applications(INDs) [EB/OL]. [2020-01]. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM610795.pdf.
[18]
Friend of Cancer Research. Designing the Future of Cellular Therapies [EB/OL]. [2019-03-31]. https://friendsofcancerresearch.org/wp-content/uploads/Friends_Cellular_Therapies_White_Paper_1.pdf
[19]
STEWART M D, KEANE A, BUTTERFIELD L H, et al. Accelerating the development of innovative cellular therapy products for the treatment of cancer [J]. Cytotherapy, 2020,22(5): 239-246.
[21]
MARCHETTI S, SCHELLENS J H M. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials [J]. Br J Cancer, 2007, 97(5): 577-581.
[23]
TEJWANI V, CHAUDHARI M, RAI T, et al. High-throughput and automation advances for accelerating single-cell cloning, monoclonality and early phase clone screening steps in mammalian cell line development for biologics production [J]. Biotechnol Prog, 2021, 37(6): e3208.
[24]
KELLEY B. Developing therapeutic monoclonal antibodies at pandemic pace [J]. Nature biotechnol, 2020, 38(5): 540-545.
[25]
ZHANG Z, CHEN J, WANG J H, et al. Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak [J]. Biotechnol Prog, 2021, 37(5):e3186.
[26]
MCGOVERN Ā T, SALISBURY C M, NYBERG G B. The pandemic and resilience for the future: AccBio 2021 [J]. Biotechnol Prog, 2022, 38(1): e3207.
[27]
崔靖,宋丽娜.创新单抗药物申报临床试验病毒安全性相关监管指南调研与技术考量[J].药学学报,2021,56(4):2308-2314.
[28]
李敏,郭秀侠,刘伯宁.关于生物制品工艺验证的审评实践与思考[J].中国生物制品学杂志,2017,30(6):664-668.
[29]
EVERS A, CLÉNET D, PFEIFFER-MAREK S. Long-term stability prediction for developability assessment of biopharmaceutics using advanced kinetic modeling [J]. Pharmaceutics, 2022, 14(2): 375.
[30]
CAMPA C, PRONCE T, PALUDI M, et al. Use of stability modeling to support accelerated vaccine development and supply [J]. Vaccines(Basel), 2021, 9(10): 1114.
[31]
FDA. Innovative Science and Technology Approaches for New Drugs(ISTAND) Pilot Program [EB/OL]. [2023-03-03]. https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/innovative-science-and-technology-approaches-new-drugs-istand-pilot-program.
[32]
DYE E, STURGESS A, MAHESHWARI G, et al. Examining manufacturing readiness for breakthrough drug development [J]. AAPS PharmSciTech, 2016, 17(3):529-538.
[33]
EFPIA-EBE. White Paper on Expedited CMC Development:Accelerated Access for Medicines of Unmet Medical Need –CMC Challenges and Opportunities [EB/OL]. [2017-12]. https://www.efpia.eu/media/288657/efpia-ebe-white-paper-expedited-cmc-development-accelerated-access-for-medicines-of-unmet-medical-need-december-2017.pdf
[34]
EMA. Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies [EB/OL]. [2018-11-26]. https://www.ema.europa.eu/en/events/stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-breakthrough
[35]
ICH Q12. Technical and regulatory considerations for pharmaceutical product lifecycle management [EB/OL]. [2019-12-20]. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf.
[36]
FDA. Chemistry, Manufacturing, and Controls Development and Readiness Pilot(CDRP) Program [EB/OL]. [2023-04-01]. https://www.fda.gov/drugs/pharmaceutical-quality-resources/chemistry-manufacturing-and-controls-development-and-readiness-pilot-cdrp-program.
2023年第54卷第6期
30
9
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2023.06.018
  • 接收时间:2022-09-20
  • 首发时间:2026-11-19
  • 出版时间:2023-06-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-09-20
基金
作者信息
    1.清华医学院,北京 100084
    2.葛兰素史克公司,北京 100025
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2023.06.018
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏